Ipilimumab vs Sitagliptin
Ipilimumab vs Sitagliptin: Overview
This comparison examines the pharmacological differences between Ipilimumab and Sitagliptin.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Sitagliptin: DPP-4 inhibitor increasing incretin levels.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Sitagliptin β 12.4 hours.
Chemical Properties
Molecular Formula: Sitagliptin β C16H15F6N5O.
Molecular Weight: Sitagliptin β 407.3140 g/mol.
Type: Ipilimumab β Antibody; Sitagliptin β Small molecule.